Skip to main content
VYNE Therapeutics Inc. logo

VYNE Therapeutics Inc. — Investor Relations & Filings

Ticker · VYNE ISIN · US92941V1008 US Manufacturing
Open in API
Filings indexed 608 across all filing types
Latest filing 2022-05-17 Regulatory Filings
Country US United States of America
Listing US VYNE

About VYNE Therapeutics Inc.

https://vynetherapeutics.com/

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company's primary objective is to address unmet medical needs by advancing a pipeline of novel drug candidates. VYNE's approach centers on innovating beyond traditional assumptions to find improved solutions for patients with complex inflammatory and immunological diseases.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 17, 2022, by VYNE Therapeutics Inc. It reports a Regulation FD Disclosure about a virtual Key Opinion Leader event and includes a presentation as an exhibit. The document does not contain financial statements or detailed financial data but rather announces an event and provides a presentation. The length is 4118 characters, which is relatively short and consistent with an announcement rather than a full report. The content fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit other more specific categories like earnings release or annual report.
2022-05-17 English
424B5
Regulatory Filings Classification · 95% confidence The document is an Amendment No. 1 to a Prospectus Supplement filed pursuant to Rule 424(b)(5), which is a regulatory filing related to securities offering. It updates the amount of shares eligible to be sold under a sales agreement and references the prospectus and prospectus supplement. The document is short (4445 characters) and serves to amend and update previous offering documents rather than being a full financial report or earnings release. It is a typical capital markets regulatory filing related to share issuance but does not itself announce a new share issue or capital change directly; rather, it amends the prospectus supplement. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and amendment filing.
2022-05-12 English
10-Q
Interim / Quarterly Report Q1 2022
2022-05-12 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions "Item 2.02 Results of Operations and Financial Condition" and references a press release announcing financial results for the quarter ended March 31, 2022. The document is short (3806 characters) and primarily serves to furnish a press release rather than containing detailed financial statements or analysis itself. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a current report filing that includes a press release but does not contain the full financial report or detailed financial data itself. It is not an Earnings Release (ER) because the document is the Form 8-K filing, not the initial announcement standalone, and it is not an Interim Report (IR) because it lacks substantive financial data and analysis. Therefore, the best classification is Regulatory Filings (RNS).
2022-05-12 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events that shareholders should know about between periodic reports. The content includes the appointment of a new independent registered public accounting firm and dismissal of the previous one, details about the audit reports, and a press release about clinical trial data. It also includes a letter from the former auditor as an exhibit. The document does not contain full financial statements or comprehensive financial performance data, but rather announces changes in auditors and other significant corporate events. This fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other specific categories like Annual Report or Audit Report. The document length is about 6,070 characters, which is consistent with a detailed 8-K filing but not a full annual or quarterly report. Therefore, the correct classification is Regulatory Filings (RNS).
2022-04-07 English
FORM 4 SUBMISSION
Director's Dealing
2022-04-04 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.